Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG monthly Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E28.54 EPS (ttm)3.14 Insider Own9.30% Shs Outstand2.29B Perf Week-0.59%
Market Cap219.78B Forward P/E14.34 EPS next Y6.24 Insider Trans0.05% Shs Float2.26B Perf Month2.71%
Income7.21B PEG4.07 EPS next Q1.42 Inst Own10.50% Short Float0.10% Perf Quarter-1.24%
Sales49.53B P/S4.44 EPS this Y-43.60% Inst Trans-3.48% Short Ratio1.28 Perf Half Y26.64%
Book/sh23.51 P/B3.81 EPS next Y9.30% ROA6.00% Target Price104.50 Perf Year2.79%
Cash/sh2.56 P/C34.92 EPS next 5Y7.02% ROE13.60% 52W Range69.18 - 99.84 Perf YTD-5.48%
Dividend3.09 P/FCF34.82 EPS past 5Y-6.50% ROI8.60% 52W High-10.99% Beta0.44
Dividend %3.45% Quick Ratio0.60 Sales past 5Y-1.90% Gross Margin71.00% 52W Low28.47% ATR1.64
Employees110000 Current Ratio0.80 Sales Q/Q-3.30% Oper. Margin18.70% RSI (14)54.06 Volatility1.72% 1.51%
OptionableYes Debt/Eq0.65 EPS Q/Q-10.30% Profit Margin14.60% Rel Volume0.64 Prev Close89.50
ShortableYes LT Debt/Eq0.48 EarningsJul 21 BMO Payout89.50% Avg Volume1.69M Price88.88
Recom1.00 SMA200.69% SMA502.88% SMA2001.06% Volume187,190 Change-0.70%
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Sep-21-20 10:08AM  
Sep-19-20 10:25AM  
10:20AM  
Sep-18-20 10:20AM  
09:51AM  
Sep-17-20 02:56PM  
11:00AM  
Sep-16-20 05:02PM  
02:00PM  
10:24AM  
Sep-15-20 08:00PM  
10:02AM  
Sep-14-20 10:50AM  
06:15AM  
01:47AM  
01:15AM  
Sep-11-20 06:42PM  
11:51AM  
11:12AM  
11:05AM  
11:00AM  
Sep-09-20 01:47AM  
Sep-08-20 01:04PM  
09:49AM  
01:15AM  
Sep-07-20 01:15AM  
Sep-01-20 01:00AM  
Aug-31-20 02:53PM  
01:34PM  
09:56AM  
09:54AM  
Aug-30-20 02:30AM  
Aug-29-20 06:30AM  
Aug-28-20 03:05PM  
Aug-27-20 09:33AM  
Aug-26-20 02:50AM  
01:15AM  
Aug-24-20 09:48AM  
03:57AM  
03:18AM  
Aug-23-20 10:08PM  
08:43AM  
Aug-22-20 06:00AM  
04:04AM  
01:15AM  
Aug-21-20 12:50PM  
10:12AM  
06:00AM  
Aug-20-20 01:30PM  
06:00AM  
Aug-17-20 01:11PM  
Aug-13-20 04:03PM  
08:18AM  
Aug-11-20 10:41AM  
Aug-07-20 11:30AM  
Aug-06-20 01:42PM  
08:13AM  
07:57AM  
Aug-05-20 05:01PM  
Aug-04-20 04:11PM  
11:38AM  
08:18AM  
01:15AM  
Aug-03-20 04:07PM  
11:54AM  
Aug-02-20 04:31PM  
Jul-31-20 03:41AM  
Jul-30-20 06:43PM  
Jul-28-20 11:40AM  
09:26AM  
Jul-27-20 03:18PM  
01:24PM  
Jul-24-20 02:06PM  
10:27AM  
Jul-22-20 09:34AM  
04:01AM  
Jul-21-20 04:22PM  
12:40PM  
12:23PM  
11:54AM  
09:54AM  
09:39AM  
09:00AM  
07:58AM  
05:16AM  
04:00AM  
01:30AM  
01:29AM  
01:00AM  
Jul-16-20 08:31AM  
07:28AM  
01:24AM  
01:15AM  
Jul-15-20 10:05PM  
09:00AM  
07:21AM  
Jul-14-20 06:42PM  
05:03PM  
Jul-13-20 06:33PM  
10:52AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 30Buy17.00125,0002,125,0001,181,258Jul 02 04:16 PM
Novartis Bioventures Ltd10% OwnerNov 12Buy12.00250,0003,000,0003,543,067Nov 12 04:15 PM